After coming off a slow third quarter, where 10 biopharma companies completed their IPOs in the U.S., collectively raising just over $1 billion, the U.S. IPO market has picked up once again. Already, as we near the end of the fourth quarter, 10 biopharma companies have graduated to the public ranks on U.S. exchanges collectively raising over $1 billion.